IRulya Therapeutics IRLA
NASDAQ IRLA
$33.78 +2.78 (+8.95%)
At close: Nov 9, 2026 · 4:00 PM EST

IRulya Therapeutics (IRLA) Restructuring Costs (2026)

Updated

IRulya Therapeutics (IRLA) reported Restructuring Costs of -$1.31 million for Q2 2026.

Analysis

IRulya Therapeutics (IRLA) Restructuring Costs (2026) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,261.99 Bn 1,235.61 Bn 20.46 Bn
2 Johnson & Johnson 678.93 Bn 598.79 Bn 17.30 Bn
3 AbbVie 518.29 Bn 486.30 Bn 13.12 Bn
4 Merck 365.98 Bn 328.92 Bn 13.19 Bn
5 Novartis Ag 316.85 Bn 290.09 Bn -
6 Astrazeneca 293.40 Bn 267.29 Bn 13.26 Bn
7 Amgen 251.78 Bn 203.43 Bn 7.58 Bn
8 Gilead Sciences 210.61 Bn 185.71 Bn 6.73 Bn
9 Pfizer 166.87 Bn 114.23 Bn 12.56 Bn
10 IRulya Therapeutics 207.35 Mn 91.35 Mn -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -1.31 Mn
API Access

IRulya Therapeutics Restructuring Costs API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=restructuring-costs&ticker=IRLA&period=max&api_key=YOUR_API_KEY